Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 575

1.

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.

Circulation. 2015 Dec 8;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857. Epub 2015 Sep 25.

PMID:
26408274
2.

Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk.

Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, Kastelein JJ; PASCAL Study Group.

J Pediatr. 2015 Aug;167(2):338-43.e5. doi: 10.1016/j.jpeds.2015.05.006. Epub 2015 Jun 6.

PMID:
26059337
3.

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ.

Lancet. 2015 Aug 1;386(9992):452-60. doi: 10.1016/S0140-6736(15)60158-1. Epub 2015 Jun 2.

PMID:
26047975
4.

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV.

J Clin Lipidol. 2015 Mar-Apr;9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7.

PMID:
25911072
5.

[The alternative view on diagnostic of hyperlipoproteinemia, cholesterol lipoproteins of low density and effect of statins: a lecture].

Tupoleva TA, Tikhomirov DS, Grumbkova LO, Ignatova EN, Romanova TIu, Filatov FP, Garanzha TA.

Klin Lab Diagn. 2015 Jan;60(1):27-38. Russian.

PMID:
25874302
6.

APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.

Lagos J, Zambrano T, Rosales A, Salazar LA.

Int J Mol Sci. 2015 Apr 9;16(4):7890-9. doi: 10.3390/ijms16047890.

7.

Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner.

Le NA, Diffenderfer MR, Thongtang N, Ooi EM, Barrett PH, Horvath KV, Dolnikowski GG, Asztalos BF, Schaefer EJ, Brown WV.

Lipids. 2015 May;50(5):447-58. doi: 10.1007/s11745-015-4005-0. Epub 2015 Mar 26.

PMID:
25809021
8.

Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).

Muntoni S, Pisciotta L, Muntoni S, Bertolini S.

J Clin Lipidol. 2015 Jan-Feb;9(1):103-6. doi: 10.1016/j.jacl.2014.08.009. Epub 2014 Aug 30.

PMID:
25670367
9.

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S.

J Clin Lipidol. 2014 Nov-Dec;8(6):568-75. doi: 10.1016/j.jacl.2014.09.002. Epub 2014 Sep 16.

PMID:
25499939
10.

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.

Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.

PMID:
25463129
11.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

12.

Chlorogenic acid protects against atherosclerosis in ApoE-/- mice and promotes cholesterol efflux from RAW264.7 macrophages.

Wu C, Luan H, Zhang X, Wang S, Zhang X, Sun X, Guo P.

PLoS One. 2014 Sep 4;9(9):e95452. doi: 10.1371/journal.pone.0095452. eCollection 2014.

13.

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ.

J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. Review.

14.

[Effect of simvastatin on atherosclerosis and central aortic pressure in ApoE gene knockout mice].

Liu M, Jin YH, Li TH, Shi LH, Zhu BQ.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):293-7. Chinese.

PMID:
24998652
15.

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.

Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB.

Vasc Health Risk Manag. 2014 May 7;10:279-90. doi: 10.2147/VHRM.S58694. eCollection 2014.

16.

Regression of atherosclerosis: insights from animal and clinical studies.

Feig JE.

Ann Glob Health. 2014 Jan-Feb;80(1):13-23. doi: 10.1016/j.aogh.2013.12.001. Epub 2013 Dec 25. Review.

17.

Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.

Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, de Graaf J, Furberg CD, Sniderman A.

J Am Heart Assoc. 2014 Apr 14;3(2):e000759. doi: 10.1161/JAHA.113.000759.

18.

A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy.

Dimick SM, Sallee B, Asztalos BF, Pritchard PH, Frohlich J, Schaefer EJ.

J Clin Lipidol. 2014 Mar-Apr;8(2):223-30. doi: 10.1016/j.jacl.2013.11.005. Epub 2013 Dec 11.

PMID:
24636183
19.

Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia.

Yamasaki T, Iwashima Y, Jesmin S, Ohta Y, Kusunoki H, Hayashi S, Horio T, Kawano Y.

PLoS One. 2014 Feb 19;9(2):e89057. doi: 10.1371/journal.pone.0089057. eCollection 2014.

20.

Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.

Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N.

Scand J Clin Lab Invest. 2014 Jun;74(4):285-95. doi: 10.3109/00365513.2014.882015. Epub 2014 Feb 24.

PMID:
24564634
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk